Categories: NewsPharmaceutical

Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum

IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the SVB Securities Therapeutics Forum.

SVB Securities Therapeutics Forum
Date: Tuesday, July 11th – Wednesday, July 12th, 2023
Location: The Lotte Palace, New York, N.Y.

About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Danielle Spangler 
Investor Relations 
Reneo Pharmaceuticals, Inc. 
dspangler@reneopharma.com

Matthew Purcell, Pharm.D.
Media Inquiries 
Russo Partners, LLC 
matthew.purcell@russopartnersllc.com

Staff

Recent Posts

uMed’s AccessCMD next-generation Cardiometabolic Cohort hits 2000 patient milestone in less than 4 months

Providing researchers with unparalleled opportunity to access novel endpoints LONDON, July 10, 2024 /PRNewswire/ -- Healthcare…

3 hours ago

New research from Dräger Safety : 94% think that Health and Safety legislation needs ‘overhauling’

BLYTH, England, July 10, 2024 /PRNewswire/ --  On the fiftieth anniversary of the main piece…

3 hours ago

Poolbeg Pharma PLC Announces Notification of Major Holdings

LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification…

6 hours ago

Evotec and Pfizer Collaborate to Advance Drug Discovery in France

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG,…

6 hours ago

IRLAB Publishes Interim Report for the Period January-June 2024

GOTHENBURG, SWEDEN / ACCESSWIRE / July 10, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…

6 hours ago

AvodahMed Names Paul Wiley as President

WESTLAKE, Texas, July 9, 2024 /PRNewswire/ -- AvodahMed is pleased to announce the appointment of…

9 hours ago